Deep learning for brain metastasis detection and segmentation in longitudinal MRI data

TL;DR

This paper introduces a novel deep learning approach with a custom loss function and temporal prior volume to significantly improve the detection and segmentation of brain metastases in longitudinal MRI data, aiding clinical decision-making.

Contribution

It proposes the volume-level sensitivity-specificity (VSS) loss and a modified DeepMedic network, DeepMedic+, to enhance metastasis detection accuracy and reduce false positives in brain MRI analysis.

Findings

Sensitivity increased from 85.3% to 97.5%.

Precision improved from 69.1% to 98.7%.

False positives reduced by 44.4%, with ensemble models achieving only 1.5 false positives per patient.

Abstract

Brain metastases occur frequently in patients with metastatic cancer. Early and accurate detection of brain metastases is very essential for treatment planning and prognosis in radiation therapy. To improve brain metastasis detection performance with deep learning, a custom detection loss called volume-level sensitivity-specificity (VSS) is proposed, which rates individual metastasis detection sensitivity and specificity in (sub-)volume levels. As sensitivity and precision are always a trade-off in a metastasis level, either a high sensitivity or a high precision can be achieved by adjusting the weights in the VSS loss without decline in dice score coefficient for segmented metastases. To reduce metastasis-like structures being detected as false positive metastases, a temporal prior volume is proposed as an additional input of DeepMedic. The modified network is called DeepMedic+ for distinction. Our proposed VSS loss improves the sensitivity of brain metastasis detection for DeepMedic, increasing the sensitivity from 85.3% to 97.5%. Alternatively, it improves the precision from 69.1% to 98.7%. Comparing DeepMedic+ with DeepMedic with the same VSS loss, 44.4% of the false positive metastases are reduced in the high sensitivity model and the precision reaches 99.6% for the high specificity model. The mean dice coefficient for all metastases is about 0.81. With the ensemble of the high sensitivity and high specificity models, on average only 1.5 false positive metastases per patient needs further check, while the majority of true positive metastases are confirmed. The ensemble learning is able to distinguish high confidence true positive metastases from metastases candidates that require special expert review or further follow-up, being particularly well-fit to the requirements of expert support in real clinical practice.